Calcitonin vs Calcitriol: How They Differ
Calcitonin and calcitriol are both calcium regulating hormones, but they belong to different chemical families. Calcitonin is a 32 amino acid peptide released by thyroid C cells that acts on a cell surface receptor and tends to lower blood calcium. Calcitriol is the active form of vitamin D, a secosteroid hormone, not a peptide, which acts on a nuclear receptor and raises calcium absorption. This page summarises what published reviews describe about source, structure, receptor type and the relationship of each to parathyroid hormone.
The short answer
Calcitonin and calcitriol are often compared because both appear in the same chapter of endocrinology textbooks, both influence circulating calcium, and both names start with the same four letters. Beyond that, they are different kinds of molecule with different origins, different receptors and generally opposite directions of effect on blood calcium.
Calcitriol is not a peptide. It is 1,25 dihydroxyvitamin D, the hormonally active form of vitamin D, and it belongs to the secosteroid family, meaning a steroid ring structure in which one ring has been opened. It is built by sequential hydroxylation of a cholesterol derived precursor, not by stringing amino acids together. Calcitonin, by contrast, is a 32 amino acid peptide hormone produced by the parafollicular C cells of the thyroid gland. A review of physiological calcium homeostasis grouped calcitonin among the calcium lowering signals that oppose parathyroid hormone action, while placing the vitamin D endocrine system among the signals that defend against low calcium by increasing absorption (PMID 16519596).
This page is for educational purposes only and is not medical advice; consult a licensed physician or qualified clinician for any question about a personal health situation, laboratory result or prescribed medicine.
Side by side comparison
| Feature | Calcitonin | Calcitriol |
|---|---|---|
| Chemical class | Peptide hormone, 32 amino acids | Secosteroid hormone, the active form of vitamin D; not a peptide |
| Primary source tissue | Parafollicular C cells of the thyroid gland | Produced by hydroxylation steps completed largely in the kidney, as described in reviews of renal mineral metabolism (PMID 34693188) |
| How it is made | Gene transcription and translation into a precursor protein that is processed to the mature peptide | Stepwise enzymatic hydroxylation of a vitamin D precursor, with the final activating step under endocrine control (PMID 18293139) |
| Receptor type | Cell surface G protein coupled receptor | Intracellular nuclear receptor (vitamin D receptor) that regulates gene transcription, a receptor also described in thyroid tissue in a review of vitamin D and thyroid tumorigenesis (PMID 23890557) |
| Speed of action | Rapid, consistent with second messenger signalling | Slower, consistent with transcriptional changes in transport proteins (PMID 16519596) |
| Direction of effect on blood calcium | Lowering, principally by restraining bone resorption, as summarised in calcium homeostasis reviews (PMID 34311095) | Raising, principally by increasing intestinal absorption of calcium and phosphate (PMID 18293139) |
| Main target tissues | Bone and kidney | Intestine, bone, kidney and parathyroid gland (PMID 34311095) |
| Relationship to parathyroid hormone | Functionally opposing arm of the calcium response (PMID 16519596) | Downstream effector of parathyroid hormone and a negative feedback signal back onto the parathyroid glands (PMID 34693188) |
Where each hormone comes from
Calcitonin
Calcitonin is synthesised in the thyroid gland, but not in the follicular cells that make thyroid hormone. It comes from a separate population of parafollicular cells, commonly called C cells. Because calcitonin is a peptide, it is encoded directly in DNA, transcribed to messenger RNA, translated as a larger precursor and then processed to the mature 32 amino acid chain. Peptide hormones of this type cannot cross the plasma membrane freely and must signal from the outside of the target cell.
Calcitriol
Calcitriol is the endpoint of a multi organ pathway rather than the product of a single gland. A vitamin D precursor is modified first in the liver and then activated by a final hydroxylation step that reviews of mineral metabolism place largely in the kidney, where its activity is regulated by parathyroid hormone, phosphate and fibroblast growth factor 23 (PMID 18293139). A 2021 review of renal contributions to age related changes in mineral metabolism reported that declining kidney function shifts this axis, with changes in the activating hydroxylation step and in the parathyroid hormone and fibroblast growth factor 23 signals that regulate it (PMID 34693188).
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeReceptors: cell surface versus nuclear
The most instructive difference is where each hormone binds. Calcitonin binds a receptor on the outer surface of target cells, a G protein coupled receptor that triggers intracellular second messengers. The effect begins quickly and fades when the signal stops, which is typical of peptide hormone signalling.
Calcitriol, being lipid soluble, diffuses into cells and binds the vitamin D receptor, a nuclear receptor that partners with a retinoid X receptor and alters transcription of target genes, including genes for calcium transport proteins. A review of vitamin D in thyroid tumorigenesis and development discussed vitamin D receptor expression and vitamin D signalling in thyroid tissue, illustrating that this nuclear receptor is distributed well beyond the classical intestinal target (PMID 23890557). Because transcription and translation of new transport proteins take time, calcitriol effects build over hours and days rather than minutes.
Opposite directions on blood calcium
Calcitriol defends against low calcium. Reviews of calcium and phosphate homeostasis describe its principal action as increasing intestinal absorption of calcium and phosphate, with additional actions at bone and kidney that are coordinated with parathyroid hormone and fibroblast growth factor 23 (PMID 18293139). A feline focused review of calcium handling physiology described the same triad of parathyroid hormone, the active vitamin D metabolite and fibroblast growth factor 23 acting through intestine, bone and kidney, with the calcium sensing receptor providing the set point (PMID 34311095).
Calcitonin pulls in the other direction. Physiological reviews place it among the hypocalcaemic signals released when calcium rises, acting chiefly to restrain osteoclast mediated bone resorption (PMID 16519596). The magnitude of that contribution varies by species and life stage, which is one reason comparative studies are informative rather than decorative. A review of calcium metabolism in birds described a system in which the demands of eggshell formation are met through hormonally driven mobilisation of skeletal calcium and intestinal absorption, with vitamin D metabolites central to the process (PMID 18165138).
Tracking research? Log entries with dates, lots and notes: records, never plans.
Get the appHow each relates to parathyroid hormone
Parathyroid hormone is the pivot that makes the comparison coherent. In the classical scheme, falling ionised calcium is sensed by the parathyroid glands, parathyroid hormone is released, and one of its downstream actions is to promote the final activation of vitamin D, which then increases intestinal calcium absorption; the resulting calcitriol in turn suppresses parathyroid hormone production, closing a feedback loop (PMID 18293139). Calcitriol is therefore best understood as a partner and effector of parathyroid hormone rather than its opponent.
Calcitonin sits on the other side of the same axis. Rather than being driven by parathyroid hormone, it is released in response to rising calcium and opposes the bone resorbing limb of the parathyroid hormone response, which is why reviews describe the two as functionally antagonistic arms of calcium control (PMID 16519596). Age related work adds a further layer: researchers reviewing renal contributions to mineral metabolism reported that changes in kidney function alter the balance between parathyroid hormone, the active vitamin D metabolite and fibroblast growth factor 23 over the lifespan (PMID 34693188).
Calcitonin vs calcitriol vs PTH in one view
- Parathyroid hormone: an 84 amino acid peptide from the parathyroid glands, released when calcium falls, acting on a cell surface receptor and driving activation of vitamin D (PMID 18293139).
- Calcitriol: a secosteroid, not a peptide, acting on a nuclear receptor, increasing intestinal calcium and phosphate absorption and feeding back on the parathyroid glands (PMID 34693188).
- Calcitonin: a 32 amino acid peptide from thyroid C cells, acting on a cell surface receptor and restraining bone resorption when calcium rises (PMID 16519596).
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeWhat comparative and life stage studies report
Reviews of fetal and neonatal mineral metabolism describe a regulatory pattern that differs from the adult one, with placental transfer and parathyroid hormone related protein taking prominent roles in maintaining fetal calcium before the newborn transitions to intestinal absorption after birth (PMID 26363942). A separate review of bone metabolism in the fetus and neonate covered the same transition and the hormonal adjustments that accompany it (PMID 23529641).
A 2018 meta-analysis of mammalian pregnancy and lactation reported measurable shifts in bone turnover and calcium homeostasis across reproductive stages, with the largest changes concentrated in lactation (PMID 29136400). In production animals, a review of endocrine pathways around parturition in dairy cows described how parathyroid hormone and vitamin D metabolite signalling are recruited to prevent periparturient hypocalcaemia (PMID 31337460). Comparative endocrinology also supplies a reminder that calcitonin is not the only calcium lowering peptide in vertebrates: a review of stanniocalcin 1 traced this hypocalcaemic glycoprotein hormone, first characterised in fish, through calcium homeostasis, insulin like growth factor signalling and tumour immunology (PMID 42446003).
Medicines and mineral balance: What Studies Report
Both calcitonin and calcitriol exist as prescription medicines under those generic names in various jurisdictions, and nothing on this page should be read as describing an approval, indication or label claim beyond what the cited sources state. A 2011 review of medications that affect calcium surveyed drug classes associated with increases or decreases in serum calcium, including agents acting through the vitamin D and bone resorption pathways, and discussed how such effects are recognised in clinical practice (PMID 21134875). The study of drug related calcium disturbance is a laboratory and clinical matter, and interpretation of any individual result belongs to a treating clinician.
No bone, fracture or osteoporosis outcome is asserted here, because the verified sources cited on this page are physiology and comparative reviews rather than clinical outcome trials. Claims about skeletal endpoints require trial data that reports those endpoints directly.
Common points of confusion
- Similar names, unrelated chemistry. Calcitonin is a peptide; calcitriol is a secosteroid. Only one of them is a peptide hormone.
- Both are called calcium hormones, but in different directions. Physiological reviews place calcitriol with the calcium raising signals and calcitonin with the calcium lowering ones (PMID 16519596).
- Calcitriol is not simply dietary vitamin D. It is the activated metabolite produced after hydroxylation steps regulated by parathyroid hormone and phosphate signals (PMID 18293139).
- Thyroid versus parathyroid. Calcitonin comes from C cells inside the thyroid gland, while parathyroid hormone comes from the separate parathyroid glands.
Related reading
References
- Recent advances in physiological calcium homeostasis (Clinical Chemistry and Laboratory Medicine, 2006)
- Calcium and phosphate homeostasis: concerted interplay of new regulators (Annals of Medicine, 2008)
- Renal Contributions to Age-Related Changes in Mineral Metabolism (JBMR Plus, 2021)
- A feline-focused review of chronic kidney disease-mineral and bone disorders Part 1: Physiology of calcium handling (The Veterinary Journal, 2021)
- Vitamin D in thyroid tumorigenesis and development (Progress in Histochemistry and Cytochemistry, 2013)
- Calcium metabolism in birds (Veterinary Clinics of North America: Exotic Animal Practice, 2008)
- Calcium, phosphorus, and bone metabolism in the fetus and newborn (Early Human Development, 2015)
- Bone metabolism in the fetus and neonate (Pediatric Nephrology, 2014)
- Changes in bone turnover and calcium homeostasis during pregnancy and lactation in mammals: a meta-analysis (Reproduction, Fertility and Development, 2018)
- Review: Endocrine pathways to regulate calcium homeostasis around parturition and the prevention of hypocalcemia in periparturient dairy cows (Animal, 2020)
- Stanniocalcin 1 at the nexus of calcium homeostasis, IGF signaling, and cancer immunity (Endocrine Reviews, 2026)
- Medications that affect calcium (Endocrine Practice, 2011)
Frequently asked questions
Is calcitriol a peptide?▾
No. Calcitriol is the active form of vitamin D and belongs to the secosteroid family, built by hydroxylation of a cholesterol derived precursor rather than from amino acids. It acts through a nuclear receptor that regulates gene transcription, a receptor described even in thyroid tissue in a review of vitamin D and thyroid tumorigenesis (PMID 23890557). Calcitonin, by contrast, is a 32 amino acid peptide.
Do calcitonin and calcitriol move blood calcium in the same direction?▾
Generally no. Reviews of physiological calcium homeostasis group calcitonin among calcium lowering signals that oppose the bone resorbing limb of parathyroid hormone action (PMID 16519596), while the active vitamin D metabolite is described as raising calcium chiefly by increasing intestinal absorption of calcium and phosphate alongside parathyroid hormone and fibroblast growth factor 23 (PMID 18293139).
How does parathyroid hormone connect the two?▾
Parathyroid hormone promotes the final activation step that produces calcitriol, and the resulting calcitriol feeds back to suppress parathyroid hormone, forming a loop described in reviews of calcium and phosphate homeostasis (PMID 18293139). Calcitonin is not downstream of parathyroid hormone; it is released as calcium rises and opposes parathyroid hormone driven bone resorption (PMID 16519596).
Why do receptor types matter in this comparison?▾
Receptor location determines speed and mechanism. Calcitonin acts at a cell surface receptor using second messengers, so effects are rapid. Calcitriol enters cells and binds the nuclear vitamin D receptor, altering transcription of calcium transport genes, which takes longer; reviews of calcium handling physiology describe this transcriptional route across intestine, bone and kidney targets (PMID 34311095).
Does the balance between these hormones change with age or reproduction?▾
Published reviews report that it does. Researchers reviewing renal contributions to mineral metabolism reported age related shifts in the active vitamin D metabolite, parathyroid hormone and fibroblast growth factor 23 (PMID 34693188). A mammalian meta-analysis reported changes in bone turnover and calcium homeostasis across pregnancy and lactation (PMID 29136400). Individual interpretation belongs to a clinician.
Are there other calcium lowering hormones besides calcitonin?▾
Yes. A review of stanniocalcin 1 traced this hypocalcaemic glycoprotein hormone, first characterised in fish, through calcium homeostasis, insulin like growth factor signalling and cancer immunity (PMID 42446003). Comparative work in birds also described species specific vitamin D driven pathways that meet the calcium demands of eggshell formation (PMID 18165138), showing that calcium control varies across vertebrates.
What do sources say about medicines that change calcium levels?▾
A 2011 review of medications that affect calcium surveyed drug classes associated with higher or lower serum calcium, including agents acting through vitamin D and bone resorption pathways, and discussed how such effects are recognised clinically (PMID 21134875). This page states no approvals, indications or doses, and any personal medication question should be directed to a licensed physician.
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education. It is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.